首页 › 基金 › a16z Capital Management, L.L.C. › DNA
a16z Capital Management, L.L.C. 对 DNA 的持仓历史
GINKGO BIOWORKS HOLDINGS INC · 医疗保健
a16z Capital Management, L.L.C. 在 Q3 2026 的 13F 申报中披露持有 DNA(GINKGO BIOWORKS HOLDINGS INC)108,568 股,市值约 US$1.4M,约占其申报组合的 0.01%,在其申报持仓中市值排名第 19 位。 a16z Capital Management, L.L.C. 最近 11 个申报季度中有 11 个季度披露了 DNA 持仓,最早可追溯至 Q1 2024。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
a16z Capital Management, L.L.C. 对 DNA 的持仓演变
a16z Capital Management, L.L.C. 于 Q1 2024 首次披露 DNA 持仓:4,342,749 股(约 US$5.0M)。 在 11 次申报中,a16z Capital Management, L.L.C. 0 次增持、1 次减持、9 次保持不变。 最近一期申报(Q3 2026)显示持股 108,568 股、市值约 US$1.4M。 持仓曾出现大幅变动:Q3 2024 减持约 98% (随后一个季度股价上涨 20%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2024 | 4.34M | $5.04M | 新进 |
| Q2 2024 | 4.34M | $1.45M | 持有 |
| Q3 2024 | 108.57K | $884.83K | 减持 |
| Q4 2024 | 108.57K | $1.07M | 持有 |
| Q1 2025 | 108.57K | $618.84K | 持有 |
| Q2 2025 | 108.57K | $1.22M | 持有 |
| Q3 2025 | 108.57K | $1.58M | 持有 |
| Q4 2025 | 108.57K | $902.20K | 持有 |
| Q1 2026 | 108.57K | $665.52K | 持有 |
| Q2 2026 | 108.57K | $1.08M | 持有 |
| Q3 2026 | 108.57K | $1.39M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 DNA 与 13F 数据
DNA(GINKGO BIOWORKS HOLDINGS INC)属于医疗保健行业。我们追踪的基金中还有 34 只申报持有 DNA,申报仓位最大的包括:Anchorage Capital Group, L.L.C. (US$22.4M), FORBES J M & CO LLP (US$12.5M), SB INVESTMENT ADVISERS (UK) LTD (US$6.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 DNA 的基金
- Anchorage Capital Group, L.L.C. 1.75M 股 · $22.41M · Q3 2026
- FORBES J M & CO LLP 977.37K 股 · $12.54M · Q3 2026
- SB INVESTMENT ADVISERS (UK) LTD 610.73K 股 · $6.05M · Q2 2026
更多关于 a16z Capital Management, L.L.C.
常见问题
How long has a16z Capital Management, L.L.C. held DNA?
a16z Capital Management, L.L.C. has disclosed DNA holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is a16z Capital Management, L.L.C.'s current position in DNA?
As of Q3 2026, a16z Capital Management, L.L.C. holds 108.57K shares of DNA (GINKGO BIOWORKS HOLDINGS INC), valued at $1.39M, representing 0.01% of its reported portfolio and ranking #19.
Has a16z Capital Management, L.L.C. been buying or selling DNA?
In the latest 13F filing (Q3 2026), a16z Capital Management, L.L.C. held unchanged its position in DNA.
Which other funds hold DNA?
Other major institutional holders of DNA include Anchorage Capital Group, L.L.C., FORBES J M & CO LLP, SB INVESTMENT ADVISERS (UK) LTD, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.